The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in The Jerusalem Post
A new implant developed at the Technion – Israel Institute of Technology may offer a self-regulating treatment for diabetes, according to a new study in collaboration with MIT, Harvard, Johns Hopkins University, and the University of Massachusetts.
The study, led by Assistant Professor Shady Farah of the Faculty of Chemical Engineering at the Technion, was peer-reviewed and was published in Science. It introduced a “living, cell-based implant” that works as a pancreas and is protected against immune rejection by a novel system.
According to the statement, the implant “continuously senses blood-glucose levels, produces insulin within the implant itself, and releases the exact amount needed – precisely when it is needed. In effect, the implant becomes a self-regulating, drug-manufacturing organ inside the body, requiring no external pumps, injections, or patient intervention.”